Production of antiviral "OP7 chimera" defective interfering particles free of infectious virus.

IF 3.9 3区 生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Applied Microbiology and Biotechnology Pub Date : 2024-12-01 Epub Date: 2024-01-13 DOI:10.1007/s00253-023-12959-6
Lars Pelz, Tanya Dogra, Pavel Marichal-Gallardo, Marc Dominique Hein, Ghada Hemissi, Sascha Young Kupke, Yvonne Genzel, Udo Reichl
{"title":"Production of antiviral \"OP7 chimera\" defective interfering particles free of infectious virus.","authors":"Lars Pelz, Tanya Dogra, Pavel Marichal-Gallardo, Marc Dominique Hein, Ghada Hemissi, Sascha Young Kupke, Yvonne Genzel, Udo Reichl","doi":"10.1007/s00253-023-12959-6","DOIUrl":null,"url":null,"abstract":"<p><p>Defective interfering particles (DIPs) of influenza A virus (IAV) are suggested for use as broad-spectrum antivirals. We discovered a new type of IAV DIP named \"OP7\" that carries point mutations in its genome segment (Seg) 7 instead of a deletion as in conventional DIPs (cDIPs). Recently, using genetic engineering tools, we generated \"OP7 chimera DIPs\" that carry point mutations in Seg 7 plus a deletion in Seg 1. Together with cDIPs, OP7 chimera DIPs were produced in shake flasks in the absence of infectious standard virus (STV), rendering UV inactivation unnecessary. However, only part of the virions harvested were OP7 chimera DIPs (78.7%) and total virus titers were relatively low. Here, we describe the establishment of an OP7 chimera DIP production process applicable for large-scale production. To increase total virus titers, we reduced temperature from 37 to 32 °C during virus replication. Production of almost pure OP7 chimera DIP preparations (99.7%) was achieved with a high titer of 3.24 log<sub>10</sub>(HAU/100 µL). This corresponded to an 11-fold increase relative to the initial process. Next, this process was transferred to a stirred tank bioreactor resulting in comparable yields. Moreover, DIP harvests purified and concentrated by steric exclusion chromatography displayed an increased interfering efficacy in vitro. Finally, a perfusion process with perfusion rate control was established, resulting in a 79-fold increase in total virus yields compared to the original batch process in shake flasks. Again, a very high purity of OP7 chimera DIPs was obtained. This process could thus be an excellent starting point for good manufacturing practice production of DIPs for use as antivirals. KEY POINTS: • Scalable cell culture-based process for highly effective antiviral OP7 chimera DIPs • Production of almost pure OP7 chimera DIPs in the absence of infectious virus • Perfusion mode production and purification train results in very high titers.</p>","PeriodicalId":8342,"journal":{"name":"Applied Microbiology and Biotechnology","volume":"108 1","pages":"97"},"PeriodicalIF":3.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10787692/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Microbiology and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s00253-023-12959-6","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Defective interfering particles (DIPs) of influenza A virus (IAV) are suggested for use as broad-spectrum antivirals. We discovered a new type of IAV DIP named "OP7" that carries point mutations in its genome segment (Seg) 7 instead of a deletion as in conventional DIPs (cDIPs). Recently, using genetic engineering tools, we generated "OP7 chimera DIPs" that carry point mutations in Seg 7 plus a deletion in Seg 1. Together with cDIPs, OP7 chimera DIPs were produced in shake flasks in the absence of infectious standard virus (STV), rendering UV inactivation unnecessary. However, only part of the virions harvested were OP7 chimera DIPs (78.7%) and total virus titers were relatively low. Here, we describe the establishment of an OP7 chimera DIP production process applicable for large-scale production. To increase total virus titers, we reduced temperature from 37 to 32 °C during virus replication. Production of almost pure OP7 chimera DIP preparations (99.7%) was achieved with a high titer of 3.24 log10(HAU/100 µL). This corresponded to an 11-fold increase relative to the initial process. Next, this process was transferred to a stirred tank bioreactor resulting in comparable yields. Moreover, DIP harvests purified and concentrated by steric exclusion chromatography displayed an increased interfering efficacy in vitro. Finally, a perfusion process with perfusion rate control was established, resulting in a 79-fold increase in total virus yields compared to the original batch process in shake flasks. Again, a very high purity of OP7 chimera DIPs was obtained. This process could thus be an excellent starting point for good manufacturing practice production of DIPs for use as antivirals. KEY POINTS: • Scalable cell culture-based process for highly effective antiviral OP7 chimera DIPs • Production of almost pure OP7 chimera DIPs in the absence of infectious virus • Perfusion mode production and purification train results in very high titers.

生产不含传染性病毒的抗病毒 "OP7 嵌合体 "缺陷干扰颗粒。
有人建议将甲型流感病毒(IAV)的缺陷干扰颗粒(DIPs)用作广谱抗病毒药物。我们发现了一种名为 "OP7 "的新型 IAV DIP,它的基因组片段(Seg)7 中带有点突变,而不是传统 DIPs(cDIPs)中的缺失。最近,我们利用基因工程工具生成了 "OP7 嵌合 DIPs",这种 DIPs 在第 7 个基因片段中携带点突变,在第 1 个基因片段中携带缺失。与 cDIPs 一起,OP7 嵌合 DIPs 是在没有传染性标准病毒(STV)的情况下在摇瓶中产生的,因此不需要紫外线灭活。然而,收获的病毒中只有一部分是 OP7 嵌合 DIPs(78.7%),病毒总滴度也相对较低。在此,我们介绍了适用于大规模生产的 OP7 嵌合体 DIP 生产工艺的建立。为提高病毒总滴度,我们在病毒复制过程中将温度从 37 ℃ 降至 32 ℃。我们生产出了几乎纯净的 OP7 嵌合体 DIP 制剂(99.7%),滴度高达 3.24 log10(HAU/100 µL)。这相当于比初始工艺提高了 11 倍。接下来,该工艺被转移到搅拌罐生物反应器中,结果产量相当。此外,通过立体排阻色谱法纯化和浓缩的 DIP 产物在体外显示出更高的干扰效力。最后,建立了一种具有灌流速率控制的灌流工艺,与摇瓶中的原始批量工艺相比,病毒总产量增加了 79 倍。此外,还获得了纯度极高的 OP7 嵌合体 DIPs。因此,该工艺是以良好生产规范生产 DIPs 用作抗病毒药物的绝佳起点。要点- 基于可扩展细胞培养的高效抗病毒 OP7 嵌合体 DIPs 生产工艺 - 在没有传染性病毒的情况下生产几乎纯净的 OP7 嵌合体 DIPs - 灌注模式生产和纯化过程可获得极高的滴度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Applied Microbiology and Biotechnology
Applied Microbiology and Biotechnology 工程技术-生物工程与应用微生物
CiteScore
10.00
自引率
4.00%
发文量
535
审稿时长
2 months
期刊介绍: Applied Microbiology and Biotechnology focusses on prokaryotic or eukaryotic cells, relevant enzymes and proteins; applied genetics and molecular biotechnology; genomics and proteomics; applied microbial and cell physiology; environmental biotechnology; process and products and more. The journal welcomes full-length papers and mini-reviews of new and emerging products, processes and technologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信